Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538181 | 1.00 | TOP1 (0.61) | TOP1MEN1KMT2A | |
| SCHEMBL26126307 | 0.92 | TOP1 (0.63) | TOP1MEN1KMT2A | |
| SCHEMBL30538170 | 0.92 | TOP1 (0.63) | TOP1MEN1KMT2A | |
| SCHEMBL25330506 | 0.92 | TOP1 (0.66) | TOP1MEN1KMT2A | |
| SCHEMBL30538205 | 0.91 | TOP1 (0.63) | TOP1MEN1KMT2A | |
| SCHEMBL26130804 | 0.91 | TOP1 (0.63) | TOP1MEN1KMT2A | |
| SCHEMBL26130880 | 0.90 | TOP1 (0.62) | TOP1MEN1KMT2A | |
| SCHEMBL30538225 | 0.90 | TOP1 (0.62) | TOP1MEN1KMT2A | |
| SCHEMBL26132434 | 0.90 | TOP1 (0.58) | TOP1MEN1KMT2A | |
| SCHEMBL23963966 | 0.90 | TOP1 (0.65) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2024-08-15 | — | — | US | disclosed |
| WO-2024082055-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024082051-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| EP-4347601-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 75/4885KMT2A 3967/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | TOP1 126/4885MEN1 2231/4885KMT2A 2538/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | TOP1 126/4885MEN1 2231/4885KMT2A 2538/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | TOP1 184/4885MEN1 1723/4885KMT2A 3039/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | TOP1 349/4885MEN1 1426/4885KMT2A 3934/4885 |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | TOP1 126/4885MEN1 2231/4885KMT2A 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.